Snapshot 5:Fri, Feb 20, 2026 2:24:55 AM GMT last edited by Kevin

Stanford Develops Nasal Spray Vaccine for Multiple Threats

Published FEB 20

story

Image credit:

The Spin

Stanford'’s breakthrough"universal" nasal spray vaccine representsis a game-changingpotential approachparadigm toshift, respiratorybreaking protection200 byyears triggeringof prolongedpathogen-specific innateshots immunitywith thata lastssingle monthsplatform ratherthat thankeeps days.lung Theimmunity vaccineon activatesstandby toll-likeagainst receptorsvirtually andany recruitsrespiratory Tthreat. cellsBy toslashing maintainviral frontlineloads defenses,up creatingto a double-whammy effect that reduces viral loads 700-fold whileand enablingtriggering rapid adaptive responses in just three days, insteadit ofcould tworeplace weeks.annual ThisCOVID-19 universaland platformflu protectsboosters againstwhile diversetargeting threats including COVID-19, influenza, bacterial pneumonia and even allergens. Such broad, potentiallyseason-proof transformingprotection medicalcould practiceblunt future pandemics and redefine the vaccine market within five to seven years.

Stanford Medicine Nature

MucosalDespite vaccinespromising facemouse fundamentaldata challengesfrom thatStanford’s parenteralintranasal vaccinationplatform, strategiesmucosal havevaccines alreadyface overcomeunresolved withtranslational provenhurdles, safetyincluding profilesweak andcorrelates regulatoryof approvalprotection, pathways.few Thesafe anatomicaladjuvants, proximityand of nasal delivery tosystems thethat centralmust nervousovercome systemmucus createsbarriers seriousand safetyachieve concerns,consistent aslung demonstrateddeposition. byComplex Bell'stissue-specific palsyimmunity, casesmicrobiome linkedvariation, tohormonal intranasaleffects, adjuvants and theantigen restrictedhoming agecomplicate range for FluMistdurability. AchievingThese durablebiological protectionand requiresformulation solvingchallenges complex— problemsnot includingproof-of-concept hormonalefficacy influences,— microbiomeremain variations and the tropicalcore barrierbottlenecks thatto reducesclinical oralscale vaccineand efficacy in low-income countriesapproval.

Linda Gay Griffith on X Nature

Metaculus Prediction

There's a 95% chance that before Jan. 1, 2032, an intranasal SARS-CoV-2 vaccine candidate will be approved by the U.S., U.K., EU or Canada, according to the Metaculus prediction community.